180 related articles for article (PubMed ID: 36829443)
1. The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure.
Takaya H; Namisaki T; Enomoto M; Kubo T; Tsuji Y; Fujinaga Y; Nishimura N; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829443
[TBL] [Abstract][Full Text] [Related]
2. Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis.
Enomoto M; Takaya H; Namisaki T; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Inoue T; Matsumoto M; Yoshiji H
Hepatol Res; 2022 Apr; 52(4):390-400. PubMed ID: 34964539
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Takaya H; Namisaki T; Shimozato N; Kaji K; Kitade M; Moriya K; Sato S; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
World J Gastrointest Oncol; 2019 May; 11(5):424-435. PubMed ID: 31139312
[TBL] [Abstract][Full Text] [Related]
4. VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
Asada S; Namisaki T; Kaji K; Takaya H; Kubo T; Akahane T; Kawaratani H; Nishimura N; Takeda S; Masuda H; Shibamoto A; Inoue T; Iwai S; Tomooka F; Tsuji Y; Fujinaga Y; Kitagawa K; Mitoro A; Sato S; Matsumoto M; Yoshiji H
Dig Dis Sci; 2024 Mar; 69(3):851-869. PubMed ID: 38244124
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.
Takaya H; Namisaki T; Asada S; Iwai S; Kubo T; Suzuki J; Enomoto M; Tsuji Y; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407443
[TBL] [Abstract][Full Text] [Related]
6. Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.
Prasanna KS; Goel A; Amirtharaj GJ; Ramachandran A; Balasubramanian KA; Mackie I; Zachariah U; Sajith KG; Elias E; Eapen CE
Indian J Gastroenterol; 2016 Nov; 35(6):432-440. PubMed ID: 27822882
[TBL] [Abstract][Full Text] [Related]
7. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
[TBL] [Abstract][Full Text] [Related]
8. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
Islek A; Ilhan D; Ozturk N; Guven B; Sag E
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
[TBL] [Abstract][Full Text] [Related]
9. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
[TBL] [Abstract][Full Text] [Related]
10. Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
Takaya H; Namisaki T; Moriya K; Shimozato N; Kaji K; Ogawa H; Ishida K; Tsuji Y; Kaya D; Takagi H; Fujinaga Y; Nishimura N; Sawada Y; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
World J Gastroenterol; 2020 Dec; 26(45):7232-7241. PubMed ID: 33362379
[TBL] [Abstract][Full Text] [Related]
11. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
[TBL] [Abstract][Full Text] [Related]
12. ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver Cirrhosis.
Suzuki J; Namisaki T; Takya H; Kaji K; Nishimura N; Shibamoto A; Asada S; Kubo T; Iwai S; Tomooka F; Takeda S; Koizumi A; Tanaka M; Matsuda T; Inoue T; Fujimoto Y; Tsuji Y; Fujinaga Y; Sato S; Kitagawa K; Kawaratani H; Akahane T; Mitoro A; Matsumoto M; Asada K; Yoshiji H
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473925
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
Tsujii N; Nogami K; Matsumoto M; Yoshizawa H; Takase T; Tanaka I; Sakai T; Fukuda K; Hayakawa M; Sakai K; Isonishi A; Matsuura K; Fujimura Y; Shima M
Thromb Res; 2019 Jul; 179():1-10. PubMed ID: 31055186
[TBL] [Abstract][Full Text] [Related]
16. Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
Takaya H; Kawaratani H; Kubo T; Seki K; Sawada Y; Kaji K; Okura Y; Takeda K; Kitade M; Moriya K; Namisaki T; Mitoro A; Matsumoto M; Fukui H; Yoshiji H
Hepatol Res; 2018 Feb; 48(3):E52-E60. PubMed ID: 28628948
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
Simbrunner B; Villesen IF; Scheiner B; Paternostro R; Schwabl P; Stättermayer AF; Marculescu R; Pinter M; Quehenberger P; Trauner M; Karsdal M; Lisman T; Reiberger T; Leeming DJ; Mandorfer M
Hepatol Int; 2023 Dec; 17(6):1532-1544. PubMed ID: 37605068
[TBL] [Abstract][Full Text] [Related]
18. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: role of elevated plasma von-Willebrand factor as predictor of mortality in patients with chronic liver disease.
Eidelberg A; Kirubakaran R; Nair SC; Eapen CE; Elias E; Goel A
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1184-1191. PubMed ID: 31498279
[TBL] [Abstract][Full Text] [Related]
20. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
